Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. To the Editor, Genes have two alleles or copies, with one inherited from each parent. The loss of one of these gene copies, termed as loss of heterozygosity (LOH), is one of the most common genetic alterations in cancer [1]. LOH has been playing a pivotal role in cancer development [2]. For instance, LOH was found to be involved in the relapse of acute lymphoblastic leukemia [3]. LOH of human leukocyte antigen (HLA) alleles hampered the ability of major histocompatibility complex to present neoantigens, thus implicating in resistance to immune checkpoint blockade (ICB) therapy [4]. Therefore, expounding the relationship between LOH and cancer will be very helpful to guide the accurate treatment. Small cell lung cancer (SCLC) is featured by rapid growth and tendency to metastasize, with grim prognosis and high relapse rate [5]. However, the landscape of LOH and its impact on prognosis and relapse has remained largely unknown in SCLC. Moreover, the association between LOH and immunological features has never been studied in SCLC. A total of 178 histologically confirmed SCLC patients were collected from Shandong Cancer Hospital and Institute. This study was approved by the Ethics Committee of Shandong Cancer Hospital and Institute. All included patients in this study offered written informed consent. Whole-exome-sequencing (WES) analyses were performed to detect the of the tumor mutational burden (TMB) and tumor neoantigen burden (TNB) for SCLC patients. We have demonstrated that SCLC patients with higher LOH were associated with lower tumor mutational burden (TMB) (R square = 0.0825, P = 0.0001; Fig. 1A). Similarly, LOH was found to be negatively associated with lower tumor neoantigen burden (TNB) (R square = 0.0726, P = 0.0003; Fig. 1B). Since CD8 + T cells are the body’s main immunological barrier against cancer and PD-L1 expression has reported to be a biomarker for immunotherapy, we next analyzed the association between CD8 + T cell infiltration, PD-L1 expression and LOH in SCLC. CD8 + TIL density and PD-L1 expression was measured using immunohistochemistry. In addition, X-tile software was applied to determine the optimal cutoff of LOH to differentiate progression free survival (PFS) (endup point for PFS: 15th, December, 2020) [6]. LOH was divided low and high in light of the optimal cutoff. The results showed that there was no significant difference in CD8 + T cell infiltration between low-LOH and high-LOH SCLC patients (P = 0.5796; Fig. 1C). SCLC patients with low LOH had numerically higher PD-L1 positive expression than those with high LOH (20.69% versus 10.83%; Fig. 1D). Importantly, in the LOH-low cohort, PFS was significantly prolonged compared with that in LOH-high cohort (P = 0.0305; Fig. 1E). Moreover, multivariate Cox regression analyses were further conducted to evaluate the prognostic factors on PFS. We have found that LOH remains to Open Access Journal of Translational Medicine


To the Editor,
Genes have two alleles or copies, with one inherited from each parent. The loss of one of these gene copies, termed as loss of heterozygosity (LOH), is one of the most common genetic alterations in cancer [1]. LOH has been playing a pivotal role in cancer development [2]. For instance, LOH was found to be involved in the relapse of acute lymphoblastic leukemia [3]. LOH of human leukocyte antigen (HLA) alleles hampered the ability of major histocompatibility complex to present neoantigens, thus implicating in resistance to immune checkpoint blockade (ICB) therapy [4]. Therefore, expounding the relationship between LOH and cancer will be very helpful to guide the accurate treatment.
Small cell lung cancer (SCLC) is featured by rapid growth and tendency to metastasize, with grim prognosis and high relapse rate [5]. However, the landscape of LOH and its impact on prognosis and relapse has remained largely unknown in SCLC. Moreover, the association between LOH and immunological features has never been studied in SCLC.
A total of 178 histologically confirmed SCLC patients were collected from Shandong Cancer Hospital and Institute. This study was approved by the Ethics Committee of Shandong Cancer Hospital and Institute. All included patients in this study offered written informed consent. Whole-exome-sequencing (WES) analyses were performed to detect the of the tumor mutational burden (TMB) and tumor neoantigen burden (TNB) for SCLC patients. We have demonstrated that SCLC patients with higher LOH were associated with lower tumor mutational burden (TMB) (R square = 0.0825, P = 0.0001; Fig. 1A). Similarly, LOH was found to be negatively associated with lower tumor neoantigen burden (TNB) (R square = 0.0726, P = 0.0003; Fig. 1B). Since CD8 + T cells are the body's main immunological barrier against cancer and PD-L1 expression has reported to be a biomarker for immunotherapy, we next analyzed the association between CD8 + T cell infiltration, PD-L1 expression and LOH in SCLC. CD8 + TIL density and PD-L1 expression was measured using immunohistochemistry. In addition, X-tile software was applied to determine the optimal cutoff of LOH to differentiate progression free survival (PFS) (endup point for PFS: 15th, December, 2020) [6]. LOH was divided low and high in light of the optimal cutoff. The results showed that there was no significant difference in CD8 + T cell infiltration between low-LOH and high-LOH SCLC patients (P = 0.5796; Fig. 1C). SCLC patients with low LOH had numerically higher PD-L1 positive expression than those with high LOH (20.69% versus 10.83%; Fig. 1D). Importantly, in the LOH-low cohort, PFS was significantly prolonged compared with that in LOH-high cohort (P = 0.0305; Fig. 1E). Moreover, multivariate Cox regression analyses were further conducted to evaluate the prognostic factors on PFS. We have found that LOH remains to

Open Access
Journal of Translational Medicine be an independent factor for predicting PFS even after adjusting for factors including age, sex, smoking, family history and stage (HR, 1.574; 95% CI 1.033-2.398; P = 0.035; Additional file 1: Table S1). Additionally, there was no significant difference in overall survival (OS) (endup point for OS: 26th, November, 2020) between LOH-low and LOH-high cohort (P = 0.2862; Fig. 1F).
To the best of our knowledge, we are the first to analyze the association between immune-related markers Fig. 1 The association of LOH with immune-related markers and the impact of LOH on survival. A The association between LOH and TMB for SCLC patients. B The association between LOH and TNB for SCLC patients. C The difference in CD8 + TIL infiltration between low-LOH and high-LOH in SCLC patients. D The difference in positive PD-L1 expression between low-LOH and high-LOH in SCLC patients. E The effect of LOH on PFS in SCLC patients. The cutoff for LOH is determined by X-tile. F The effect of LOH on OS in SCLC patients